<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="editorial"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Protein Cell</journal-id><journal-id journal-id-type="iso-abbrev">Protein Cell</journal-id><journal-title-group><journal-title>Protein &#x00026; Cell</journal-title></journal-title-group><issn pub-type="ppub">1674-800X</issn><issn pub-type="epub">1674-8018</issn><publisher><publisher-name>Higher Education Press</publisher-name><publisher-loc>Beijing</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6160391</article-id><article-id pub-id-type="publisher-id">503</article-id><article-id pub-id-type="doi">10.1007/s13238-017-0503-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Commentary</subject></subj-group></article-categories><title-group><article-title>IFN-&#x003bb;: A new spotlight in innate immunity against influenza virus infection</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Yeping</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Jiang</surname><given-names>Jingwen</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Tien</surname><given-names>Po</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Wenjun</given-names></name><address><email>liuwj@im.ac.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Jing</given-names></name><address><email>lj418@163.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000000119573309</institution-id><institution-id institution-id-type="GRID">grid.9227.e</institution-id><institution>CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, </institution><institution>Chinese Academy of Sciences, </institution></institution-wrap>Beijing, 100101 China </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2018</year></pub-date><volume>9</volume><issue>10</issue><fpage>832</fpage><lpage>837</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; HEP and Springer-Verlag GmbH Germany, part of Springer Nature 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="Par1">Influenza virus is a long-lasting and severe threat to human health. Seasonal flu epidemics, which are caused by the co-circulating influenza A viruses (IAVs) and influenza B viruses (IBVs), occur annually and lead to tens of millions of respiratory illnesses and up to half a million human deaths worldwide each year (Ginsberg et al., <xref ref-type="bibr" rid="CR16">2009</xref>). Influenza pandemics are more devastating. The 2009 swine-originated H1N1 virus, which caused the latest influenza pandemic, spread from Mexico and U.S. to virtually all countries throughout the world within only several months and was associated much higher mortality among children, young adults, and pregnant women than typical seasonal influenza viruses (Fineberg, <xref ref-type="bibr" rid="CR13">2014</xref>). The zoonotic avian influenza viruses, including H5N1, H5N6, H7N9 and H10N8, cause alarmingly high fatality rate in human cases, raising a public concern of pandemic influenza outbreak of avian origin (Poovorawan et al., <xref ref-type="bibr" rid="CR27">2013</xref>; Barr, <xref ref-type="bibr" rid="CR2">2017</xref>; Bui et al., <xref ref-type="bibr" rid="CR7">2017</xref>).</p><p id="Par2">Innate immune system is an important barrier of defending against influenza virus infection. According to the traditional paradigm, after IAV gets across the mucus that covers the respiratory epithelium, it first invades and infects respiratory epithelial cells, from where it spreads to other non-immune and immune cells (e.g., macrophages and dendritic cells). In these cells, the virus can be sensed by the pattern recognition receptors (PRRs), triggering the production of type I interferons (IFNs) which induce the expression of hundreds of IFN-stimulated genes (ISGs) that block viral replication and further virus spread. Simultaneously, activation of PRRs also leads to production of pro-inflammatory cytokines (IL-6, IL-1&#x003b2;, IL-18, TNF, etc.) and chemokines. Pro-inflammatory cytokines induce topical and systemic inflammation, cause fever and anorexia, and direct the adaptive immune response against the virus. Chemokines, on the other hand, recruit innate immune cells (neutrophils, monocytes, and NK cells) which engulf and inactivate the virus, kill virally infected cells, and guide subsequent innate and adaptive immune responses that mediate ultimate viral clearance (Iwasaki and Pillai, <xref ref-type="bibr" rid="CR18">2014</xref>).</p><p id="Par3">However, effective protection from influenza virus&#x000a0;infection is provided by finely tuned antiviral immunity, while excessive innate immunity causes detrimental inflammation. Infection with influenza viruses is usually self-limited, though the severe cases, especially caused by highly virulent strains (e.g., the 2009 pandemic H1N1 virus, H5N1 and H7N9) are characterized by severe pulmonary disease and lethal acute respiratory distress syndrome (ARDS) (Bauer et al., <xref ref-type="bibr" rid="CR3">2006</xref>; Ramsey and Kumar, <xref ref-type="bibr" rid="CR28">2011</xref>; Ma et al., <xref ref-type="bibr" rid="CR22">2017</xref>). Influenza-induced ARDS, which involves the damage to the epithelial-endothelial barrier of the pulmonary alveolus, flute leakage to the alveolar lumen, and respiratory insufficiency, is associated not only with direct viral damage to epithelial-endothelial barrier, but also with inflammation mediated by components of the innate immune response. The cytokines produced in influenza virus infected epithelial and endothelial cells, and cytokines and reactive oxygen species produced by neutrophils and macrophages recruited to pulmonary alveolus all contribute to damage to the epithelial-endothelial barrier (Short et al., <xref ref-type="bibr" rid="CR30">2014</xref>).</p><p id="Par4">Both the protective and pathological roles of innate immunity have been evidenced in human and experimental animals. On one hand, genetic deficiency in production of interferon or certain ISGs (e.g., MX and IFITM proteins) increases the vulnerability to IAV infection (Ciancanelli et al., <xref ref-type="bibr" rid="CR10">2015</xref>, <xref ref-type="bibr" rid="CR11">2016</xref>). On the other hand, genetic ablation of the pro-inflammatory cytokine IL-6 (Dienz et al., <xref ref-type="bibr" rid="CR12">2012</xref>), or chemical depletion of alveolar macrophages (Abboud et al., <xref ref-type="bibr" rid="CR1">2015</xref>), NK (Abboud et al., <xref ref-type="bibr" rid="CR1">2015</xref>) or neutrophils (Tate et al., <xref ref-type="bibr" rid="CR31">2009</xref>) in mice can exacerbate lung injury during IAV infection. These data support that both IFN response and inflammatory innate immune response are essential in protecting the host against IAV infections. However, gene expression analysis displays that early innate immunity signatures including pro-inflammatory cytokines (TNF, IL-1&#x003b2;, IL-6), chemokines (CCL2, CCL3, CCL4, CXCL1) and neutrophil infiltration are strongly associated with acute death of the mice infected with IAV (Brandes et al., <xref ref-type="bibr" rid="CR5">2013</xref>). In addition, deletion of pro-inflammatory cytokines IL-1, TNF and various chemokines decrease mortality in IAV-infected mice (Teijaro, <xref ref-type="bibr" rid="CR32">2015</xref>). Furthermore, hyper expression of pro-inflammatory cytokines and chemokines are linked to the high mortality in human cases infected with highly pathogenic influenza virus strains such as 1918 pandemic H1N1 virus and H5N1 virus (Loo and Gale, <xref ref-type="bibr" rid="CR21">2007</xref>; Peiris et al., <xref ref-type="bibr" rid="CR25">2009</xref>). These data suggest that exaggerate inflammation during lethal infection with IAV can have fatal consequences. Therefore, benign outcomes of influenza virus infection results from inducing sufficient IFN-mediated antiviral immunity while avoiding harmful inflammatory response.</p><p id="Par5">Most current knowledge about innate immunity in influenza virus infection has come from IAV. Although IBV contributes a significant part to the burden arising from the worldwide epidemics of seasonal influenza, much less attention has been paid to IBV than IAV because IBV does not have a potential to cause a pandemic (Chai et al., <xref ref-type="bibr" rid="CR8">2017</xref>). IBV is characterized by strict host range limits, initiates local epidemics with a lower evolutionary rate and causes milder clinical syndrome than IAV (Jiang et al., <xref ref-type="bibr" rid="CR19">2016</xref>). However, little is known about the innate response against the IBV infection.</p><p id="Par6">Recently, we investigated the global transcriptome of the human lung A549 cell line infected with IBV with RNA-seq. We identified 340 differentially expressed genes (DEGs) in these cells at 8&#x000a0;h after infection. Among them, we found that type III IFNs (including IFN-&#x003bb;1, IFN-&#x003bb;2, and IFN-&#x003bb;3) were among the top highly up-regulated genes. However, type I IFNs (IFN-&#x003b1;/&#x003b2;) was not significantly up-regulated and not listed among the DEGs. Besides, various antiviral ISGs including almost all known antiviral effectors in the innate immune system, including OAS proteins, MX proteins, IFITM proteins, and viperin (Schneider et al., <xref ref-type="bibr" rid="CR29">2014</xref>), are also highly up-regulated.</p><p id="Par7">To verify this, we performed a qPCR analysis to determine the expression level of IFNs genes, as well as three important antiviral ISGs: Mx1, ISG20 and IFITM1 at 4, 8, and 12&#x000a0;h post infection. Consistent with the&#x000a0;RNA-seq&#x000a0;data analysis, IFN-&#x003bb; expression was significantly increased at all the time points. The Mx1, ISG20 and IFITM1 also displayed markedly altered mRNA levels during IBV infection. In contrast, the expression of IFN-&#x003b1; was not altered at all points (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A). Since the function of both IFN-&#x003bb; and IFN-&#x003b1; is induction of ISG expression <italic>via</italic> the same intracellular signaling pathways, we speculate that it is IFN-&#x003bb; rather than IFN-&#x003b1; that dominates the production of ISGs in IBV-infected A549 cells. Indeed, the IBV NP protein levels were obviously decreased in IFN-&#x003bb; stimulated A549 cells, indicating the potent antiviral activity during IBV replication in A549 cell (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B).<fig id="Fig1"><label>Figure&#x000a0;1</label><caption><p><bold>The integrated signaling pathway for IBV infection in A549 cells</bold>. (A) qRT-PCR analysis of the expression of selected genes in IBV infected A549 cells compared with uninfected controls. The fold difference was determined using the 2<sup>&#x02212;&#x02206;&#x02206;Ct</sup> method, and RNA levels were normalized to GAPDH. Error bars represent the standard deviation. (B) A549 cells were treated with recombinant human IFN-&#x003bb; (R&#x00026;D systems) at final concentration of 0, 20, 50 and 100&#x000a0;ng/mL, followed by infection with IBV for 12&#x000a0;h. Cell lysates were analyzed by western blot using indicated antibodies. (C) The pathways for IBV infection in A549 cells. The relative expression values are indicated by the color gradient. The full lines represent direct interactions, and the dashed lines represent indirect interactions. The uncolored ellipses represent genes that are not DEGs. ISGs are marked with an asterisk</p></caption><graphic xlink:href="13238_2017_503_Fig1_HTML" id="MO1"/></fig>
<fig id="Fig2"><label>Figure&#x000a0;2</label><caption><p><bold>Different gene expression pattern triggered by type I and type III IFNs</bold>. Type III IFNs (IFN-&#x003bb;3, PDB ID: 5T5W) binding to their heterodimeric receptor composed of IFN&#x003bb;R1 and IL-10R&#x003b2; triggers the formation of heterdimeric complex of STAT1 and STAT2 which translocates to the nucleus where it forms ternary complex with IRF9 and form IFN-stimulated gene factor 3 (IGF3). IGF3 binds to IFN-stimulated response elements (ISREs) and induces the expression of antiviral ISGs. Engagement of type I IFNs (IFN-&#x003b1;2, PDB ID: 3SE3) with their receptor, the heterodimer composed of IFNAR1 and IFNAR2, can also activate the STAT1 homodimer which binds to gamma-activated sequence (GAS) and induces the expression of pro-inflammatory cytokines and chemokines</p></caption><graphic xlink:href="13238_2017_503_Fig2_HTML" id="MO2"/></fig></p><p id="Par8">Based on the above results and KEGG pathways assay, we built the intracellular signaling pathway related to IBV infection in A549 cells (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C). IBV infection begins with viral HA binding to &#x003b1;-2,3 or &#x003b1;-2,6 sialic acid on the host cell surface. After binding to the receptor, the virus enters the endosome, where the acidic environment triggers virus-host cell membrane fusion, after which the viral RNA is released into the cytoplasm. In the cytoplasm, the virus-derived RNA is recognized by multiple canonical pattern recognition receptors (PRRs), including the RIG-I-like receptors (RLRs, RIG-I, and MD5), the Toll-like receptors (TLRs, TLR-3, and 7), the NOD-like receptors (NLR and NOD1/2), and the PKR, and activates their respective signaling pathways. Activation of these pathways leads to the expression of IFN-&#x003bb;s, which then interact with their receptor, the heterogeneous dimer IFNLR1/IL-10R, and activate the expression of ISGs through the JAK/STAT pathway.</p><p id="Par9">Interferons (IFNs) are classified into three categories (type I IFNs, type II IFNs, and type III IFNs). All IFNs signal through JAK/STAT pathway which leads to transcription of ISGs, but their production cells and receptor specificity are different (Chow and Gale, <xref ref-type="bibr" rid="CR9">2015</xref>). Type I IFNs include IFN-&#x003b1;, &#x003b2;, &#x003b5;, &#x003ba;, and &#x003c9;. They can be produced by almost all cell types and their receptor is the widely-expressed heterodimer composed of IFNR1 and IFNR2. Type II IFN is INF-&#x003b3;, which is produced by immune cells and forms dimmer to act on the receptor complex consisting of two IFNR1 and two IFNR2. Type III IFNs include IFN-&#x003bb;1 (IL-29), IFN-&#x003bb;2 (IL-28A), IFN-&#x003bb;3 (IL-28B), and IFN-&#x003bb;4. Their receptor is the heterodimeric complex composed of IFN-&#x003bb;R1 and IL-10R&#x003b2;. IL-10R&#x003b2; is broadly distributed, but the expression of IFN-&#x003bb;R1 is mainly restricted to epithelial cells (Broggi et al., <xref ref-type="bibr" rid="CR6">2017</xref>).</p><p id="Par10">Although discovered later than type I and type II IFNs, type III IFNs in innate immunity are attracting more and more attention. The potential importance of type III IFNs has been suggested by life-threatening influenza developed in genetically deficiency that leads to impaired production of both type I and type III IFN production in a 9-year-old child (Ciancanelli et al., <xref ref-type="bibr" rid="CR10">2015</xref>). IFNLR is expressed by human hepatocytes, and IFNL polymorphisms are associated with ameliorated outcome from HCV and HBV infection (Bibert et al., <xref ref-type="bibr" rid="CR4">2013</xref>; Galmozzi et al., <xref ref-type="bibr" rid="CR15">2014</xref>). Clinical trials have displayed that the pegylated IFN-&#x003bb; can reduce the level of HCV and HBV in patients infected with chronic HCV and HBV, respectively (Zeuzem et al., <xref ref-type="bibr" rid="CR33">2011</xref>; Phillips et al., <xref ref-type="bibr" rid="CR26">2017</xref>). IFN-&#x003bb;s are also highly expressed in gastrointestinal tracts, and can cure chronic murine norovirus infection without the presence of adaptive immunity (Nice et al., <xref ref-type="bibr" rid="CR24">2015</xref>).</p><p id="Par11">Most recently, several important breakthroughs have increased the brightness of IFN-&#x003bb;s as a new spotlight in innate immunity. One of them is the determination of the crystal structure of an engineered high-affinity IFN-&#x003bb;3 (H11) in complex with its two receptors, IFN-&#x003bb;R1 and IL-10R. In this structure, the IFN-&#x003bb;3 helical bundle binds to the gorge formed by the two domains at the distal ends of its two receptors to the cellular membrane. In contrast, the two receptors bind to the opposite sides of the helical bundles of type I IFNs (Mendoza et al., <xref ref-type="bibr" rid="CR23">2017</xref>).</p><p id="Par12">Another breakthrough is the definition of the differential roles of IFN-&#x003bb;s in contrast to type I IFNs in IAV infection using Ifnlr1<sup>&#x02212;/&#x02212;</sup>, Ifn&#x003b1;r1<sup>&#x02212;/&#x02212;</sup> and Ifnlr1<sup>&#x02212;/&#x02212;</sup> Ifn&#x003b1;r1<sup>&#x02212;/&#x02212;</sup> mice (Galani et al., <xref ref-type="bibr" rid="CR14">2017</xref>). This study shows that in mice infected with IAV, IFN-&#x003bb;s emerge earlier than type I IFNs and show potent protective function during the early phase of the infection, when type I IFNs are still scarce. Furthermore, IFN-&#x003bb;s treatment induces expression of antiviral genes but not pro-inflammatory cytokines in neutrophils, while type I IFNs induce the expression of both types of genes and are involved in causing inflammation and&#x000a0;immunopathology.</p><p id="Par13">The different functions between IFN-&#x003bb;s and type I IFNs can be explained by the different STAT complex they activated. When engaged with their receptor complexes, both IFN-&#x003bb;s and type I IFNs activate JAK-family kinases, which phosphorylate STAT1 and STAT2. The phosphorylated STAT1 and STAT2 dimerize and translocate to the nucleus where they associate with IRF9 to form IFN-stimulated gene factor 3 (ISGF3), bind to IFN-stimulated response elements (ISREs) and induces the expression of antiviral ISGs. However, engagement of type I IFNs with their receptor can also activate the STAT1 homodimer which binds to gamma-activated sequence (GAS) and induces the expression of pro-inflammatory cytokines and chemokines (Ivashkiv and Donlin, <xref ref-type="bibr" rid="CR17">2014</xref>). Thus, type I IFNs have the potential of inducing inflammation in addition to antiviral function, while IFN-&#x003bb;s promote the production of antiviral ISGs without the function of inducing inflammation (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).</p><p id="Par14">In summary, IFN-&#x003bb;s are more advantageous than type I IFNs in defending against influenza virus for several reasons: (1) IFN-&#x003bb;s are produced earlier and in larger amount during influenza virus infection; (2) unlike type I IFNs, IFN-&#x003bb;s are produced and act specifically in respiratory tract, so they do not induce systematic side effects; (3) type III IFNs have potent antiviral activity without mediating inflammation. Therefore, IFN-&#x003bb;s share the therapeutic benefits but eschews many side effects associated with the clinical use of IFN-&#x003b1;/&#x003b2; (Lazear et al., <xref ref-type="bibr" rid="CR20">2015</xref>). In the future, scientists should explore the possibility that whether IFN-&#x003bb;s are more ideal therapeutic reagents for dealing with respiratory tract infection by viruses like IBV or not.</p></body><back><ack><title>Acknowledgements</title><p>We gratefully thank Dr. Jun Wu of the Institute of Microbiology, Chinese Academy of Sciences, for helpful suggestions. This work was supported by grants from the National Key R&#x00026;D Program of China (2016YFD0500206, 2017YFD051105, 2016YFC1200803, and 2016YFC1201303), National Natural Science Foundation of China (Grant Nos. 31572526, 31402216 and 31630079), National Defense Foundation of China (Grant No. 17-163-12-ZT-005-041-01), the Southeast Asia Biodiversity Research Institute, Chinese Academy of Sciences (Y4ZK111B01). Wenjun Liu and Po Tian are the principal investigators of the NSFC Innovative Research Group (Grant No. 81621091).</p><p>JL and YS designed the experiments, performed RNA-sequencing and other experimental data analysis, prepared the manuscript, and completed its revision. JL and JJ performed the viral replication ability tests. WL and PT provided helpful suggestions about the study. All authors read and approved the final manuscript. All of the authors declare that they have no conflict of interest.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abboud</surname><given-names>G</given-names></name><name><surname>Tahiliani</surname><given-names>V</given-names></name><name><surname>Desai</surname><given-names>P</given-names></name><name><surname>Varkoly</surname><given-names>K</given-names></name><name><surname>Driver</surname><given-names>J</given-names></name><name><surname>Hutchinson</surname><given-names>TE</given-names></name><name><surname>Salek-Ardakani</surname><given-names>S</given-names></name></person-group><article-title>Natural killer cells and innate interferon gamma participate in the host defense against respiratory vaccinia virus infection</article-title><source>J Virol</source><year>2015</year><volume>90</volume><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1128/JVI.01894-15</pub-id><?supplied-pmid 4702563?><pub-id pub-id-type="pmid">26468539</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barr</surname><given-names>IG</given-names></name></person-group><article-title>Assessing the potential pandemic risk of recent avian influenza viruses</article-title><source>Eur Respir J</source><year>2017</year><volume>49</volume><fpage>1602517</fpage><pub-id pub-id-type="doi">10.1183/13993003.02517-2016</pub-id><pub-id pub-id-type="pmid">28275178</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>TT</given-names></name><name><surname>Ewig</surname><given-names>S</given-names></name><name><surname>Rodloff</surname><given-names>AC</given-names></name><name><surname>Muller</surname><given-names>EE</given-names></name></person-group><article-title>Acute respiratory distress syndrome and pneumonia: a comprehensive review of clinical data</article-title><source>Clin Infect Dis</source><year>2006</year><volume>43</volume><fpage>748</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1086/506430</pub-id><pub-id pub-id-type="pmid">16912951</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bibert</surname><given-names>S</given-names></name><name><surname>Roger</surname><given-names>T</given-names></name><name><surname>Calandra</surname><given-names>T</given-names></name><name><surname>Bochud</surname><given-names>M</given-names></name><name><surname>Cerny</surname><given-names>A</given-names></name><name><surname>Semmo</surname><given-names>N</given-names></name><name><surname>Duong</surname><given-names>FHT</given-names></name><name><surname>Gerlach</surname><given-names>T</given-names></name><name><surname>Malinverni</surname><given-names>R</given-names></name><name><surname>Moradpour</surname><given-names>D</given-names></name><etal/></person-group><article-title>IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction</article-title><source>J Exp Med</source><year>2013</year><volume>210</volume><fpage>1109</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1084/jem.20130012</pub-id><?supplied-pmid 3674704?><pub-id pub-id-type="pmid">23712427</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandes</surname><given-names>M</given-names></name><name><surname>Klauschen</surname><given-names>F</given-names></name><name><surname>Kuchen</surname><given-names>S</given-names></name><name><surname>Germain</surname><given-names>RN</given-names></name></person-group><article-title>A systems analysis identifies a feedforward inflammatory circuit leading to lethal influenza infection</article-title><source>Cell</source><year>2013</year><volume>154</volume><fpage>197</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.06.013</pub-id><?supplied-pmid 3763506?><pub-id pub-id-type="pmid">23827683</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broggi</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Granucci</surname><given-names>F</given-names></name><name><surname>Zanoni</surname><given-names>I</given-names></name></person-group><article-title>IFN-lambda suppresses intestinal inflammation by non-translational regulation of neutrophil function</article-title><source>Nat Immunol</source><year>2017</year><volume>18</volume><fpage>1084</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1038/ni.3821</pub-id><pub-id pub-id-type="pmid">28846084</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bui</surname><given-names>CM</given-names></name><name><surname>Chughtai</surname><given-names>AA</given-names></name><name><surname>Adam</surname><given-names>DC</given-names></name><name><surname>MacIntyre</surname><given-names>CR</given-names></name></person-group><article-title>An overview of the epidemiology and emergence of influenza A infection in humans over time</article-title><source>Arch Public Health</source><year>2017</year><volume>75</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1186/s13690-017-0182-z</pub-id><?supplied-pmid 5366997?><pub-id pub-id-type="pmid">28352464</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>N</given-names></name><name><surname>Swem</surname><given-names>LR</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>G</given-names></name><name><surname>Chiang</surname><given-names>N</given-names></name><name><surname>Estevez</surname><given-names>A</given-names></name><name><surname>Fong</surname><given-names>R</given-names></name><name><surname>Kamen</surname><given-names>L</given-names></name><name><surname>Kho</surname><given-names>E</given-names></name><name><surname>Reichelt</surname><given-names>M</given-names></name><etal/></person-group><article-title>A broadly protective therapeutic antibody against influenza B virus with two mechanisms of action</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>14234</fpage><pub-id pub-id-type="doi">10.1038/ncomms14234</pub-id><?supplied-pmid 5253702?><pub-id pub-id-type="pmid">28102191</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>KT</given-names></name><name><surname>Gale</surname><given-names>M</given-names><suffix>Jr</suffix></name></person-group><article-title>SnapShot: interferon signaling</article-title><source>Cell</source><year>2015</year><volume>163</volume><issue>1808&#x02013;1808</issue><fpage>e1801</fpage></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciancanelli</surname><given-names>MJ</given-names></name><name><surname>Huang</surname><given-names>SX</given-names></name><name><surname>Luthra</surname><given-names>P</given-names></name><name><surname>Garner</surname><given-names>H</given-names></name><name><surname>Itan</surname><given-names>Y</given-names></name><name><surname>Volpi</surname><given-names>S</given-names></name><name><surname>Lafaille</surname><given-names>FG</given-names></name><name><surname>Trouillet</surname><given-names>C</given-names></name><name><surname>Schmolke</surname><given-names>M</given-names></name><name><surname>Albrecht</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>448</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1126/science.aaa1578</pub-id><?supplied-pmid 4431581?><pub-id pub-id-type="pmid">25814066</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciancanelli</surname><given-names>MJ</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>SY</given-names></name><name><surname>Casanova</surname><given-names>JL</given-names></name></person-group><article-title>Host genetics of severe influenza: from mouse Mx1 to human IRF7</article-title><source>Curr Opin Immunol</source><year>2016</year><volume>38</volume><fpage>109</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2015.12.002</pub-id><?supplied-pmid 4733643?><pub-id pub-id-type="pmid">26761402</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dienz</surname><given-names>O</given-names></name><name><surname>Rud</surname><given-names>JG</given-names></name><name><surname>Eaton</surname><given-names>SM</given-names></name><name><surname>Lanthier</surname><given-names>PA</given-names></name><name><surname>Burg</surname><given-names>E</given-names></name><name><surname>Drew</surname><given-names>A</given-names></name><name><surname>Bunn</surname><given-names>J</given-names></name><name><surname>Suratt</surname><given-names>BT</given-names></name><name><surname>Haynes</surname><given-names>L</given-names></name><name><surname>Rincon</surname><given-names>M</given-names></name></person-group><article-title>Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung</article-title><source>Mucosal Immunol</source><year>2012</year><volume>5</volume><fpage>258</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1038/mi.2012.2</pub-id><?supplied-pmid 3328598?><pub-id pub-id-type="pmid">22294047</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fineberg</surname><given-names>HV</given-names></name></person-group><article-title>Pandemic preparedness and response&#x02014;lessons from the H1N1 influenza of 2009</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><fpage>1335</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1208802</pub-id><pub-id pub-id-type="pmid">24693893</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galani</surname><given-names>IE</given-names></name><name><surname>Triantafyllia</surname><given-names>V</given-names></name><name><surname>Eleminiadou</surname><given-names>EE</given-names></name><name><surname>Koltsida</surname><given-names>O</given-names></name><name><surname>Stavropoulos</surname><given-names>A</given-names></name><name><surname>Manioudaki</surname><given-names>M</given-names></name><name><surname>Thanos</surname><given-names>D</given-names></name><name><surname>Doyle</surname><given-names>SE</given-names></name><name><surname>Kotenko</surname><given-names>SV</given-names></name><name><surname>Thanopoulou</surname><given-names>K</given-names></name><etal/></person-group><article-title>Interferon-lambda mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness</article-title><source>Immunity</source><year>2017</year><volume>46</volume><issue>875&#x02013;890</issue><fpage>e876</fpage></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galmozzi</surname><given-names>E</given-names></name><name><surname>Vigano</surname><given-names>M</given-names></name><name><surname>Lampertico</surname><given-names>P</given-names></name></person-group><article-title>Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?</article-title><source>Aliment Pharmacol Ther</source><year>2014</year><volume>39</volume><fpage>569</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1111/apt.12631</pub-id><pub-id pub-id-type="pmid">24461198</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginsberg</surname><given-names>J</given-names></name><name><surname>Mohebbi</surname><given-names>MH</given-names></name><name><surname>Patel</surname><given-names>RS</given-names></name><name><surname>Brammer</surname><given-names>L</given-names></name><name><surname>Smolinski</surname><given-names>MS</given-names></name><name><surname>Brilliant</surname><given-names>L</given-names></name></person-group><article-title>Detecting influenza epidemics using search engine query data</article-title><source>Nature</source><year>2009</year><volume>457</volume><fpage>U1012</fpage><lpage>U1014</lpage><pub-id pub-id-type="doi">10.1038/nature07634</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivashkiv</surname><given-names>LB</given-names></name><name><surname>Donlin</surname><given-names>LT</given-names></name></person-group><article-title>Regulation of type I interferon responses</article-title><source>Nat Rev Immunol</source><year>2014</year><volume>14</volume><fpage>36</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1038/nri3581</pub-id><?supplied-pmid 4084561?><pub-id pub-id-type="pmid">24362405</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwasaki</surname><given-names>A</given-names></name><name><surname>Pillai</surname><given-names>PS</given-names></name></person-group><article-title>Innate immunity to influenza virus infection</article-title><source>Nat Rev Immunol</source><year>2014</year><volume>14</volume><fpage>315</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1038/nri3665</pub-id><?supplied-pmid 4104278?><pub-id pub-id-type="pmid">24762827</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>JW</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>WH</given-names></name><name><surname>Zheng</surname><given-names>WN</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Bi</surname><given-names>YH</given-names></name><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name><etal/></person-group><article-title>Robust Lys63-linked ubiquitination of RIG-I promotes cytokine eruption in early influenza B virus infection</article-title><source>J Virol</source><year>2016</year><volume>90</volume><fpage>6263</fpage><lpage>6275</lpage><pub-id pub-id-type="doi">10.1128/JVI.00549-16</pub-id><?supplied-pmid 4936144?><pub-id pub-id-type="pmid">27122586</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazear</surname><given-names>HM</given-names></name><name><surname>Nice</surname><given-names>TJ</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name></person-group><article-title>Interferon-lambda: immune functions at barrier surfaces and beyond</article-title><source>Immunity</source><year>2015</year><volume>43</volume><fpage>15</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.07.001</pub-id><?supplied-pmid 4527169?><pub-id pub-id-type="pmid">26200010</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loo</surname><given-names>YM</given-names></name><name><surname>Gale</surname><given-names>M</given-names><suffix>Jr</suffix></name></person-group><article-title>Influenza: fatal immunity and the 1918 virus</article-title><source>Nature</source><year>2007</year><volume>445</volume><fpage>267</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1038/445267a</pub-id><pub-id pub-id-type="pmid">17230179</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Dai</surname><given-names>Q</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Deng</surname><given-names>F</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><etal/></person-group><article-title>Predictors for fatal human infections with avian H7N9 influenza, evidence from four epidemic waves in Jiangsu Province, Eastern China, 2013&#x02013;2016</article-title><source>Influenza Other Respir Viruses</source><year>2017</year><volume>11</volume><fpage>418</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1111/irv.12461</pub-id><?supplied-pmid 5596522?><pub-id pub-id-type="pmid">28675634</pub-id></element-citation></ref><ref id="CR23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendoza</surname><given-names>JL</given-names></name><name><surname>Schneider</surname><given-names>WM</given-names></name><name><surname>Hoffmann</surname><given-names>HH</given-names></name><name><surname>Vercauteren</surname><given-names>K</given-names></name><name><surname>Jude</surname><given-names>KM</given-names></name><name><surname>Xiong</surname><given-names>A</given-names></name><name><surname>Moraga</surname><given-names>I</given-names></name><name><surname>Horton</surname><given-names>TM</given-names></name><name><surname>Glenn</surname><given-names>JS</given-names></name><name><surname>de Jong</surname><given-names>YP</given-names></name><etal/></person-group><article-title>The IFN-lambda-IFN-lambdaR1-IL-10Rbeta complex reveals structural features underlying type III IFN functional plasticity</article-title><source>Immunity</source><year>2017</year><volume>46</volume><fpage>379</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.02.017</pub-id><?supplied-pmid 5510750?><pub-id pub-id-type="pmid">28329704</pub-id></element-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nice</surname><given-names>TJ</given-names></name><name><surname>Baldridge</surname><given-names>MT</given-names></name><name><surname>McCune</surname><given-names>BT</given-names></name><name><surname>Norman</surname><given-names>JM</given-names></name><name><surname>Lazear</surname><given-names>HM</given-names></name><name><surname>Artyomov</surname><given-names>M</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Virgin</surname><given-names>HW</given-names></name></person-group><article-title>Interferon-lambda cures persistent murine norovirus infection in the absence of adaptive immunity</article-title><source>Science</source><year>2015</year><volume>347</volume><fpage>269</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1126/science.1258100</pub-id><pub-id pub-id-type="pmid">25431489</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>JS</given-names></name><name><surname>Cheung</surname><given-names>CY</given-names></name><name><surname>Leung</surname><given-names>CY</given-names></name><name><surname>Nicholls</surname><given-names>JM</given-names></name></person-group><article-title>Innate immune responses to influenza A H5N1: friend or foe?</article-title><source>Trends Immunol</source><year>2009</year><volume>30</volume><fpage>574</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1016/j.it.2009.09.004</pub-id><?supplied-pmid 5068224?><pub-id pub-id-type="pmid">19864182</pub-id></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>S</given-names></name><name><surname>Mistry</surname><given-names>S</given-names></name><name><surname>Riva</surname><given-names>A</given-names></name><name><surname>Cooksley</surname><given-names>H</given-names></name><name><surname>Hadzhiolova-Lebeau</surname><given-names>T</given-names></name><name><surname>Plavova</surname><given-names>S</given-names></name><name><surname>Katzarov</surname><given-names>K</given-names></name><name><surname>Simonova</surname><given-names>M</given-names></name><name><surname>Zeuzem</surname><given-names>S</given-names></name><name><surname>Woffendin</surname><given-names>C</given-names></name><etal/></person-group><article-title>Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis B patients</article-title><source>Front Immunol</source><year>2017</year><volume>8</volume><fpage>621</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00621</pub-id><?supplied-pmid 5446997?><pub-id pub-id-type="pmid">28611778</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poovorawan</surname><given-names>Y</given-names></name><name><surname>Pyungporn</surname><given-names>S</given-names></name><name><surname>Prachayangprecha</surname><given-names>S</given-names></name><name><surname>Makkoch</surname><given-names>J</given-names></name></person-group><article-title>Global alert to avian influenza virus infection: from H5N1 to H7N9</article-title><source>Pathog Glob Health</source><year>2013</year><volume>107</volume><fpage>217</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1179/2047773213Y.0000000103</pub-id><?supplied-pmid 4001451?><pub-id pub-id-type="pmid">23916331</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramsey</surname><given-names>C</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>H1N1: viral pneumonia as a cause of acute respiratory distress syndrome</article-title><source>Curr Opin Crit Care</source><year>2011</year><volume>17</volume><fpage>64</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1097/MCC.0b013e3283427259</pub-id><pub-id pub-id-type="pmid">21157318</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>WM</given-names></name><name><surname>Chevillotte</surname><given-names>MD</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name></person-group><article-title>Interferon-stimulated genes: a complex web of host defenses</article-title><source>Annu Rev Immunol</source><year>2014</year><volume>32</volume><fpage>513</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120231</pub-id><?supplied-pmid 4313732?><pub-id pub-id-type="pmid">24555472</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Short</surname><given-names>KR</given-names></name><name><surname>Kroeze</surname><given-names>E</given-names></name><name><surname>Fouchier</surname><given-names>RAM</given-names></name><name><surname>Kuiken</surname><given-names>T</given-names></name></person-group><article-title>Pathogenesis of influenza-induced acute respiratory distress syndrome</article-title><source>Lancet Infect Dis</source><year>2014</year><volume>14</volume><fpage>57</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(13)70286-X</pub-id><pub-id pub-id-type="pmid">24239327</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tate</surname><given-names>MD</given-names></name><name><surname>Deng</surname><given-names>YM</given-names></name><name><surname>Jones</surname><given-names>JE</given-names></name><name><surname>Anderson</surname><given-names>GP</given-names></name><name><surname>Brooks</surname><given-names>AG</given-names></name><name><surname>Reading</surname><given-names>PC</given-names></name></person-group><article-title>Neutrophils ameliorate lung injury and the development of severe disease during influenza infection</article-title><source>J Immunol</source><year>2009</year><volume>183</volume><fpage>7441</fpage><lpage>7450</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0902497</pub-id><pub-id pub-id-type="pmid">19917678</pub-id></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teijaro</surname><given-names>JR</given-names></name></person-group><article-title>The role of cytokine responses during influenza virus pathogenesis and potential therapeutic options</article-title><source>Curr Top Microbiol Immunol</source><year>2015</year><volume>386</volume><fpage>3</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">25267464</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeuzem</surname><given-names>S</given-names></name><name><surname>Arora</surname><given-names>S</given-names></name><name><surname>Bacon</surname><given-names>B</given-names></name><name><surname>Box</surname><given-names>T</given-names></name><name><surname>Charlton</surname><given-names>M</given-names></name><name><surname>Diago</surname><given-names>M</given-names></name><name><surname>Dieterich</surname><given-names>D</given-names></name><name><surname>Mur</surname><given-names>RE</given-names></name><name><surname>Everson</surname><given-names>G</given-names></name><name><surname>Fallon</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pegylated interferon-Lambda (PEGIFN-lambda) shows superior viral response with improved safety and tolerability versus PEGIFN alpha-2A in HCV patients (G1/2/3/4): emerge phase IIB through week 12</article-title><source>J Hepatol</source><year>2011</year><volume>54</volume><fpage>S538</fpage><lpage>S539</lpage><pub-id pub-id-type="doi">10.1016/S0168-8278(11)61362-7</pub-id></element-citation></ref></ref-list></back></article>